Biotech Values

[DewDiligence]

Adam Feuerstein botched the discussion of the Bydureon trial:

http://www.thestreet.com/story/11031389/4/biotech-stock-mailbag-to-dividend-or-not.html

…statistically speaking, Bydureon failed to demonstrate "non-inferiority" or equivalent efficacy. In plain English, the study showed Victoza works better at lowering blood glucose than Bydureon.

Wrong, Adam. Failure to show statsig non-inferiority is not the same thing as showing statsig inferiority.